Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients

PURPOSE: Tenofovir disoproxil (TD), modified from tenofovir disoproxil fumarate (TDF), was developed as a salt-free formulation, removing fumarate to improve the ease of oral intake by reducing the tablet’s size. We evaluated the maintenance of antiviral effects and overall safety profile of TD 245...

Descripción completa

Detalles Bibliográficos
Autores principales: Yim, Hyung Joon, Kim, Ji Hoon, Cho, Yong Kyun, Kweon, Young Oh, Cho, Hyun Chin, Hwang, Jae Seok, Lee, Changhyeong, Koh, Moon Soo, Baek, Yang-Hyun, Park, Young-Min, Lee, Jeong-Hoon, Kim, Seung Up, Kang, Min-Kyu, Park, Neung Hwa, Lee, June Sung, Chon, Young Eun, Cheon, Gab Jin, Chae, Hee Bok, Sohn, Joo Hyun, Lim, Young-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514787/
https://www.ncbi.nlm.nih.gov/pubmed/36177347
http://dx.doi.org/10.2147/DDDT.S376821

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514787/
https://www.ncbi.nlm.nih.gov/pubmed/36177347
http://dx.doi.org/10.2147/DDDT.S376821

Ejemplares similares